Weekly Recap | Revolution Medicines -8.17%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.The Week
Revolution Medicines (RVMD) fell 8.17% this week to close at $189.76, while the S&P 500 gained 1.15%, leaving the stock roughly 9.32 percentage points behind the benchmark. Trading was choppy: it opened Monday at $207.68 and touched a weekly high of $210.27, then slid through Tuesday and Wednesday. Thursday brought the sharpest leg down, with the low at $180.49, before a modest bounce on Friday to close at $189.76. Weekly amplitude came to 14.34%.
Key Events
The company’s main news was the 5 October announcement that it started a Phase 3 trial, RASolute 309, for the daraxonrasib and zoldonrasib combination in first-line metastatic RAS G12D pancreatic cancer. In parallel, sector sentiment softened. Biotech stocks tumbled on 7 October, with recent winners Moderna and Vaxcyte among the biggest losers. Revolution Medicines dropped more than 8% intraday on 8 October and extended losses past 10%, with pancreatic cancer drug data concerns continuing to weigh on the stock into 9 October.
Analyst Ratings
Among 24 institutions covering the stock, 18 rate it buy, 5 rate it overweight, and 1 rates it hold, with no underweight or sell ratings. The consensus rating is strong buy. The consensus target price is about $259.14, roughly 36.56% above the current price. The target range is wide, from $179 to $320, pointing to notable disagreement. Within 508 names in the biotech sector, the stock ranks 16th by analyst rating.
The Week Ahead
The macro calendar is relatively busy next week. US CPI and core CPI are due on 14 October, with CPI at a prior 3.4 against a forecast of 3.7, and core CPI at a prior 2.4 against 2.5. NFIB small business sentiment and existing home sales are scheduled for 13 October. On the company side, updates on enrolment and further read-throughs from pancreatic cancer drug data could keep RASolute 309 in focus.
In Short
The tension this week is between a Phase 3 start and a mostly buy-rated analyst base on one side, and a sharp sell-off driven by biotech weakness and pancreatic cancer data concerns on the other. The stock fell nearly 10% relative to the S&P 500. In the latest trading day, small and medium orders were net buyers while large-lot inflow was modest. The next watch points are CPI data and any fresh signals from RASolute 309.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.